Jones, Lauren A;
Brierley, Daniel I;
(2025)
GLP-1 and the Neurobiology of Eating Control: Recent
Advances.
Endocrinology
, 166
(2)
10.1210/endocr/bqae167.
Preview |
Text
Brierley_GLP-1 and the Neurobiology of Eating Control_bqae167.pdf Download (2MB) | Preview |
Abstract
Obesity is now considered a chronic relapsing progressive disease, associated with increased all-cause mortality that scales with body weight, affecting more than 1 billion people worldwide. Excess body fat is strongly associated with excess energy intake, and most successful anti-obesity medications (AOMs) counter this positive energy balance through the suppression of eating to drive weight loss. Historically, AOMs have been characterized by modest weight loss and side effects which are compliance-limiting, and in some cases life-threatening. However, the field of obesity pharmacotherapy has now entered a new era of AOMs based on analogues of the gut hormone and neuropeptide glucagon-like peptide-1 (GLP-1). The latest versions of these drugs elicit unprecedented levels of weight loss in clinical trials, which are now starting to be substantiated in real-world usage. Notably, these drugs reduce weight primarily by reducing energy intake, via activation of the GLP-1 receptor on multiple sites of action primarily in the central nervous system, although the most relevant sites of action, and the neural circuits recruited remain contentious. Here we provide a targeted synthesis of recent developments in the field of GLP-1 neurobiology, highlighting studies which have advanced our understanding of how GLP-1 signaling modulates eating, and identify open questions and future challenges we believe still need to be addressed to aid the prevention and/or treatment of obesity.
| Type: | Article |
|---|---|
| Title: | GLP-1 and the Neurobiology of Eating Control: Recent Advances |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1210/endocr/bqae167 |
| Publisher version: | https://doi.org/10.1210/endocr/bqae167 |
| Language: | English |
| Additional information: | © The Author(s), 2025. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC-BY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Keywords: | eating, feeding, obesity, GLP-1, glucagon-like peptide-1, semaglutide, liraglutide |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > Div of Biosciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > Div of Biosciences > Neuro, Physiology and Pharmacology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10203680 |
Loading...
Loading...Loading...| 1. |  United Kingdom | 3 |
| 2. |  United States | 3 |
| 3. |  Japan | 1 |
| 4. |  Austria | 1 |
| 5. |  India | 1 |
Archive Staff Only
 |
View Item |
